Description
Tesamorelin is a synthetic 44-amino-acid analog of growth hormone–releasing hormone (GHRH), engineered with an N-terminal trans-3-hexenoic acid modification that confers resistance to DPP-IV proteolytic cleavage and extends the plasma half-life relative to native GHRH. Developed by Theratechnologies and FDA-approved as Egrifta® in 2010 for the reduction of excess visceral adipose tissue in HIV-associated lipodystrophy, Tesamorelin functions as a selective GHRH receptor agonist that stimulates pulsatile endogenous growth hormone release from the anterior pituitary, with downstream hepatic IGF-1 production. The compound has been investigated in preclinical and clinical research for visceral adipose tissue (VAT) endpoints, body composition, lipid metabolism, hepatic steatosis, and cognitive function, and is one of the most extensively characterized stabilized GHRH analogs in research literature.
Benefits (Research Focus)
• GHRH receptor agonism — studied for selective stimulation of the GHRH receptor and pulsatile growth hormone release
• IGF-1 axis activation — investigated for downstream hepatic IGF-1 production and somatotropic signaling
• Visceral adipose tissue research — explored for VAT-specific endpoints in lipodystrophy and metabolic models
• Lipid metabolism — examined for hepatic lipid handling and triglyceride pathway endpoints
• DPP-IV resistance — researched for extended pharmacokinetic profile via trans-3-hexenoic acid N-terminal modification
What Researchers Look At
• Plasma GH and IGF-1 dynamics following GHRH receptor stimulation
• Visceral adipose tissue (VAT) measurements via CT or MRI in lipodystrophy research models
• Pulsatile vs sustained GH release patterns and downstream somatotropic endpoints
• Hepatic steatosis, liver fat fraction, and ALT/AST endpoints
• Comparative pharmacology versus CJC-1295 (DAC and No DAC variants), sermorelin, and other GHRH analogs
Quick Specs
• Form: Lyophilized white powder
• Net Peptide Content: 10 mg per vial
• Quantity: 1 vial
• Appearance: White to off-white lyophilizate
• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)
• Purity: ≥99% by HPLC
• Identity: MS-verified (per COA)
• Storage: Protect from light
Identity Basics
• Compound: Tesamorelin
• Synonyms: TH9507; Egrifta (FDA-approved brand name); trans-3-hexenoyl-GHRH(1-44)
• Class: Stabilized GHRH(1-44) analog; selective GHRH receptor agonist; 44 amino acids
• Modification: N-terminal trans-3-hexenoic acid (hexenoyl) modification for DPP-IV resistance and extended half-life
• Formula / M.W.: C221H366N72O67S, ~5135.86 g/mol
• CAS: 218949-48-5
⚠️ Disclaimer
- This product is intended for laboratory research use only.
- Not for human or veterinary use.
- Not approved for diagnostic, therapeutic, or medical applications.
- Handle using appropriate laboratory safety procedures and personal protective equipment.
COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.
Janoshik COA — Third-Party Testing
• Tesamorelin 10mg Batch COA — September 24, 2025
• Tesamorelin VPeptide Canada — March 24, 2026
• Tesamorelin VPeptide Canada — June 5, 2026
• Tesamorelin VPeptide Canada — Batch# TSM08-2110 – Peptide Test Canada – sale item
